Capricor Therapeutics, Inc. $CAPR Shares Sold by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. trimmed its holdings in Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 16.7% in the third quarter, Holdings Channel.com reports. The institutional investor owned 135,413 shares of the biotechnology company’s stock after selling 27,123 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Capricor Therapeutics were worth $976,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. KLP Kapitalforvaltning AS grew its stake in shares of Capricor Therapeutics by 65.2% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company’s stock valued at $108,000 after purchasing an additional 4,300 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Capricor Therapeutics by 6.8% during the second quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock worth $9,565,000 after purchasing an additional 61,701 shares during the period. HBK Sorce Advisory LLC grew its position in Capricor Therapeutics by 33.7% in the 3rd quarter. HBK Sorce Advisory LLC now owns 170,577 shares of the biotechnology company’s stock valued at $1,141,000 after buying an additional 42,951 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Capricor Therapeutics in the 2nd quarter valued at $135,000. Finally, Citizens Financial Group Inc. RI increased its stake in Capricor Therapeutics by 249.2% in the 2nd quarter. Citizens Financial Group Inc. RI now owns 35,000 shares of the biotechnology company’s stock valued at $348,000 after buying an additional 24,977 shares during the period. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Trading Down 5.2%

Shares of CAPR opened at $22.45 on Monday. The firm’s 50-day moving average is $25.70 and its two-hundred day moving average is $13.78. Capricor Therapeutics, Inc. has a twelve month low of $4.30 and a twelve month high of $40.37. The firm has a market capitalization of $1.03 billion, a P/E ratio of -12.47 and a beta of 0.38.

Analyst Ratings Changes

Several analysts have recently commented on the stock. iA Financial set a $48.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. HC Wainwright increased their price target on shares of Capricor Therapeutics from $24.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, December 3rd. Roth Mkm lifted their price objective on Capricor Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Wall Street Zen downgraded Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Finally, Maxim Group raised their price target on Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.82.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.